Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Atazanavir Sulfate

FDA-approved product (capsule, oral), marketed as Atazanavir Sulfate, Reyataz.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Atazanavir Sulfate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Protease inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AE08

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli48.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Atazanavir Sulfate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Atazanavir Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Disulfiram Interactions With HIV Medications: Clinical Implications

    NCT00878306 · start 2008-11

    Registered record
    Registry ID
    NCT00878306
    Conditions
    HIV Infections; Drug Abuse
    Interventions
    Disulfiram; Disulfiram + Efavirenz; Disulfiram + Atazanavir; Disulfiram + Ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-11
    Completion
    2013-04
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Drug Abuse
    InterventionDisulfiram; Disulfiram + Efavirenz; Disulfiram + Atazanavir; Disulfiram + Ritonavir
    PhasePhase 1
    Registry statusCompleted

  • Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r

    NCT00756730 · start 2008-09

    Registered record
    Registry ID
    NCT00756730
    Conditions
    HIV Infections
    Interventions
    ATV/r; DRV/r
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-09
    Completion
    2011-06
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionATV/r; DRV/r
    PhasePhase 4
    Registry statusCompleted

  • Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir

    NCT00708162 · start 2008-07

    Registered record
    Registry ID
    NCT00708162
    Conditions
    HIV Infection
    Interventions
    Elvitegravir; Raltegravir; EVG placebo; RAL placebo; Background regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-07
    Completion
    2015-04
    Enrolment
    724

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionElvitegravir; Raltegravir; EVG placebo; RAL placebo +1 more
    PhasePhase 3
    Registry statusCompleted

  • Raltegravir and Atazanavir Replacing Current Suppressive Treatment Because of Side Effects in Current Treatment

    NCT00751153 · start 2008-03

    Registered record
    Registry ID
    NCT00751153
    Conditions
    HIV Infections
    Interventions
    Raltegravir and Atazanavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2008-03
    Completion
    2009-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionRaltegravir and Atazanavir
    PhasePhase 4
    Registry statusUnknown

  • Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects (Study P04875)

    NCT00551018 · start 2007-12

    Registered record
    Registry ID
    NCT00551018
    Conditions
    HIV Infections
    Interventions
    Vicriviroc; emtricitabine and tenofovir disoproxil fumarate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-12
    Completion
    2010-10
    Enrolment
    218

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionVicriviroc; emtricitabine and tenofovir disoproxil fumarate
    PhasePhase 2
    Registry statusCompleted

  • Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection

    NCT00440947 · start 2007-03

    Registered record
    Registry ID
    NCT00440947
    Conditions
    Infection, Human Immunodeficiency Virus I; HIV Infection
    Interventions
    Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r); Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-03
    Completion
    2010-07
    Enrolment
    515

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection, Human Immunodeficiency Virus I; HIV Infection
    InterventionAbacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r); Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV)
    PhasePhase 3
    Registry statusCompleted

  • ALTAIR - Alternative Antiretroviral Strategies : a Comparison of Three Initial Regimens

    NCT00335322 · start 2007-02

    Registered record
    Registry ID
    NCT00335322
    Conditions
    Human Immunodeficiency Virus (HIV)
    Interventions
    Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin (efavirenz); Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV); Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-02
    Completion
    2011-11
    Enrolment
    329

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus (HIV)
    InterventionTruvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin (efavirenz); Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV); Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)
    PhasePhase 4
    Registry statusCompleted

  • Pharmacokinetic Study of 2 Doses of ATV/r OD + 2 NRTIs in Thai HIV-1 Infected Patients

    NCT00411957 · start 2007-01

    Registered record
    Registry ID
    NCT00411957
    Conditions
    HIV Infections
    Interventions
    Atazanavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2007-01
    Completion
    2008-01
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionAtazanavir
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Metabolic Effects of Switching Kaletra to Boosted Reyataz

    NCT00413153 · start 2006-05

    Registered record
    Registry ID
    NCT00413153
    Conditions
    HIV Infections
    Interventions
    atazanavir/ritonavir; lopinavir/ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-05
    Completion
    2008-12
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventionatazanavir/ritonavir; lopinavir/ritonavir
    PhaseNot applicable
    Registry statusCompleted

  • PK of Once Daily ART Containing Tenofovir and Atazanavir/Ritonavir

    NCT00273273 · start 2006-02

    Registered record
    Registry ID
    NCT00273273
    Conditions
    HIV Infections
    Interventions
    blood draw
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2006-02
    Completion
    2007-12
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventionblood draw
    PhaseNot recorded
    Registry statusCompleted

  • Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings

    NCT00084136 · start 2005-05

    Registered record
    Registry ID
    NCT00084136
    Conditions
    HIV Infections
    Interventions
    Atazanavir; Didanosine (enteric-coated); Efavirenz; Emtricitabine; Emtricitabine/Tenofovir disoproxil fumarate; Lamivudine/Zidovudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-05
    Completion
    2010-05
    Enrolment
    1,571

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionAtazanavir; Didanosine (enteric-coated); Efavirenz; Emtricitabine +2 more
    PhasePhase 4
    Registry statusCompleted

  • "The Once A Day Protease Inhibitor Regimens"

    NCT00242216 · start 2004-05

    Registered record
    Registry ID
    NCT00242216
    Conditions
    HIV Infections
    Interventions
    ritonavir-boosted atazanavir; ritonavir-boosted fosamprenavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-05
    Completion
    2010-03
    Enrolment
    76

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventionritonavir-boosted atazanavir; ritonavir-boosted fosamprenavir
    PhasePhase 4
    Registry statusCompleted

  • A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen

    NCT00135343 · start 2004-04

    Registered record
    Registry ID
    NCT00135343
    Conditions
    HIV Infections
    Interventions
    Atazanvir/ritonavir + efavirenz; Atazanvir/ritonavir + efavirenz
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-04
    Completion
    2005-10
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionAtazanvir/ritonavir + efavirenz; Atazanvir/ritonavir + efavirenz
    PhasePhase 3
    Registry statusCompleted

  • Atazanavir or Boosted Atazanavir Substitution for Ritonavir Boosted PI in Patients With Hyperlipidemia

    NCT00160329 · start 2004-01

    Registered record
    Registry ID
    NCT00160329
    Conditions
    Hyperlipidemia; HIV Infections
    Interventions
    Atazanavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-01
    Completion
    2009-03
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperlipidemia; HIV Infections
    InterventionAtazanavir
    PhasePhase 3
    Registry statusCompleted

  • Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir/Ritonavir on Cardiovascular Disease Risk Factors

    NCT00720590 · start 2003-11

    Registered record
    Registry ID
    NCT00720590
    Conditions
    Endothelial Dysfunction
    Interventions
    Atazanavir; Lopinavir/ritonavir; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2003-11
    Completion
    2006-10
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndothelial Dysfunction
    InterventionAtazanavir; Lopinavir/ritonavir; Placebo
    PhaseNot applicable
    Registry statusCompleted